Home › Meningioma › New York
Meningioma clinical trials in New York
9 studies for Meningioma are looking for participants at sites in New York.
Cities in New York
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Glens Falls Hospital, Glens Falls
- Northwell Health/Center for Advanced Medicine, Lake Success
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT02523014Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
- NYU Lagone Health, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06955169A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
- Memorial Sloan-Kettering Cancer Center, New York
- Mayo Clinic_Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT07428616Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
- New York University Langone Medical Center, New York
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT04374305A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
- NYU- Langone Health, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07533942Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
- Albany Medical Center, Albany
- SUNY Upstate Medical Center, Syracuse
- Montefiore Einstein, The Bronx
- and 1 more
RecruitingObservational study
All ages · All sexes · Updated Jul 22, 2026 · NCT04427384Cabozantinib for Patients With Recurrent or Progressive Meningioma
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 14, 2026 · NCT05425004Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
- New York-Presbyterian/Weill Cornell Medical Center, New York
RecruitingPhase 4
Ages 18 to 99 · All sexes · Updated Feb 27, 2026 · NCT0637737168-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
- Weill Cornell Medicine, New York
RecruitingPhase 4
Ages 18 to 100 · All sexes · Updated Nov 21, 2025 · NCT04081701From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.